MK-1092 / Merck (MSD) - LARVOL DELTA

A randomized, single ascending dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of a novel insulin dimer. (PubMed, Clin Pharmacol Ther) - P1 | "MK-1092 did not prevent a subsequent high dose of Humalog® from increasing the GIR in healthy adults. Additional studies in adults with T1D and T2D are needed to further evaluate the safety, tolerability, and efficacy profile of MK-1092 and its potential for differentiation from more conventional insulins. ClinicalTrials.gov: NCT03170544."

Clinical • Journal • PK/PD data • Diabetes • Hypoglycemia • Metabolic Disorders • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

Discovery of Insulin Receptor Partial Agonists MK-5160 and MK-1092 as Novel Basal Insulins with Potential to Improve Therapeutic Index. (PubMed, J Med Chem) - "IRPAs had a prolonged duration of action, potentially making them suitable for once-daily dosing. Two lead compounds with %Max values of 30 and 40% relative to native insulin were selected for follow up studies in the clinic."

Journal • Diabetes • Hypoglycemia • Metabolic Disorders • IR